RxDoctor Payments Data

Christopher Pittman, MD

Family Medicine · Rogers, ARNPI 1407860539

Payments from drug & device makers

$4,913in general payments, 2019–2025

Across 309 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$668
  • AbbVie$565
  • AstraZeneca$538
  • Astellas Pharma US Inc$447
  • GSK$412
  • Merck$295
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$4,913100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,913 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$95,271
Medicare patients
112
Services billed
2,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$109,215
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$73,639
FarxigaDapagliflozin Propanediol51$50,884
EliquisApixaban41$36,171
JardianceEmpagliflozin26$30,242
MounjaroTirzepatide17$26,276
TrulicityDulaglutide14$18,957
EntrestoSacubitril/Valsartan18$15,116
JanuviaSitagliptin Phosphate23$14,357
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$13,793
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,724
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$4,468
SymbicortBudesonide/Formoterol Fumarate17$4,371
PremarinEstrogens, Conjugated11$3,296
PaxlovidNirmatrelvir/Ritonavir18$2,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$219$109,21599 claims
GSKTrelegy Ellipta$412$73,63981 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$538$61,97979 claims
Lilly USA, LLCMounjaro, Trulicity$26$45,23331 claims
PfizerEliquis, Premarin, Paxlovid$172$42,18670 claims
Boehringer IngelheimJardiance$98$30,24226 claims
NovartisEntresto$73$15,11618 claims
MerckJanuvia$295$14,35723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Rogers

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →